




Xlife sciences

THE LEADING EUROPEAN LIFE SCIENCES INCUBATOR AND ACCELERATOR



NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, INTO THE UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION WOULD BE UNLAWFUL

The presentation has been prepared by Xlife Sciences Ltd. ("Xlife", and together with its subsidiaries, the "Xlife Group") for information and background purposes only. This document is not, and should not be construed as, a prospectus or offering document, and has not been reviewed or approved by any regulatory or supervisory authority. The information does not constitute or form part of, and should not be construed as, an offer for sale or subscription of, or a solicitation or invitation of any offer to subscribe for or purchase any loans or securities of or make an investment in Xlife or any other member of the Xlife Group or any other entity in any jurisdiction, and nothing contained therein shall form the basis of, or be relied on in connection with, any contract or commitment whatsoever, in particular, it must not be used in making any investment decision.

No representation, warranty or undertaking, express or implied, is made by Xlife or any member of the Xlife Group or any of their respective affiliates or directors, officers, employees, agents or advisers ("Representatives") or any other person as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained therein or any other statement made or purported to be made in connection with Xlife, the Xlife Group or any member thereof, for any purpose whatsoever, including but not limited to any investment considerations. No responsibility, obligation or liability whatsoever, whether arising in tort, contract or otherwise, is or will be accepted by Xlife or any member of the Xlife Group or any of their respective Representatives or any other person for any loss, cost or damage howsoever arising from any use of the information, or for information or opinions or for any errors, omissions or misstatements contained therein or otherwise arising in connection therewith.

This presentation contains forward-looking statements, including but not limited to, projections of financial developments, market activities, future performance of products and solutions or planned transactions, which involve risks and uncertainties and are based on certain assumptions. These forward-looking statements are subject to change based on known or unknown risks and various other factors, which could cause the actual results, performance or events to differ materially from the statements made herein. If any of these risks and uncertainties materializes or if the assumptions underlying any of Xlife's forward-looking statements prove to be incorrect, the actual results may be materially different from those Xlife expresses or implies by such statements. Xlife does not intend or assume any obligation to update these forward-looking statements since they are based solely on the circumstances at the date of their publication.

The securities mentioned herein will not be registered under the United States Securities Act of 1933, as amended (the "Act"), and such securities may not be offered or sold in the United States of America absent registration or an applicable exemption from registration requirements under the Act. This presentation is not a prospectus for the purposes of Regulation (EU) 2017/1129 (as amended) and Regulation (EU) 2017/1129 as it forms part of domestic law pursuant to the European Union (Withdrawal) Act 2018.

COMPANY OVERVIEW

Xlife Sciences is a Swiss life sciences incubator and accelerator.

2019

LAUNCH
WITH 6 PROJECT COMPANIES

1

STOCK EXCHANGE
SPARKS SEGMENT SIX SWISS EXCHANGE
SINCE FEBRUARY 2022,
PREVIOUS MUNICH STOCK EXCHANGE

~5.77 M

SHARES
5.767.572 SHARES WITH A NOMINAL
VALUE OF CHF 1

50.2%

FREE FLOAT
42,8% FOUNDERS, 7% MANAGEMENT

~133 M

MARKET CAPITALIZATION
June 2026

>40/100k

INNOVATION PARTNERS
WITH UNIVERSITIES, RESEARCH
INSTITUTIONS & INDUSTRY PARTNERS /
ACCESS TO SCIENTISTS

19/4/33

PORTFOLIO COMPANIES
IN 4 INVESTMENT PILLARS
WITH 33 PROJECTS

>20

EMPLOYEES
XLIFE SCIENCES AG /
PROJECT COMPANIES

Xlife Sciences supports researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts.

~300

INVENTION DISCLOSURES P.A.

~3-5

NEW PROJECT COMPANIES P.A.

~1.5 M

FINANCING

~500k

POTENTIAL GRANTS

WHERE WE ADD VALUE TO OUR PROJECT COMPANIES

PROOF OF
CONCEPT

M&A

MARKETING

HR

STRUCTURING


BUSINESS
DEVELOPMENT

RESEARCH

PATENTING

LICENSING

BREAKDOWN BY PROJECT DEVELOPMENT PHASE




EXIT STRATEGIES

LICENSE DEAL

TRADE SALE

IPO

INVESTMENT PROCESS



MANAGEMENT



Oliver R. Baumann
Chief Executive Officer



Carl von Halem
Chief Financial Officer



Dr. Alexander Zink
Chief Scientific Officer



Dr. Frank Plöger
MD Xlife Sciences USA



Christian Faber
Head of Legal & Compliance



Beat Kläui
Head of Accounting and Taxes

BOARD OF DIRECTORS



David L. Deck
President of the Board of Directors



Désirée A. Dosch
Member of the Board of Directors



Dr. Norbert Windhab
Member of the Board of Directors



Mark S. Müller
Member of the Board of Directors



Oliver R. Baumann
Member of the Board of Directors



Prof. Dr. habil. Michael B. Klein
Politics Expert



Prof. Dr. Ernst Rietschel
Immunology Expert



Prof. Dr. Hans-Georg Rammensee
Immunology Expert



Prof. Dr. Johannes Schumacher
Human Genetics Expert



Dr. Christoph Brücher
Industry Expert



Dr. med. Uwe Rudolf
Max Reuter, DM
Head Physician at Klinik Im Leben



Dr. med. Ralf Oettmeier
Head Physician at Alpstein Clinic



Dr. Bernward Garthoff
Industry Expert



Prof. Dr. Jürgen Eckel
Diabetes Expert




Prof. Dr. Ulrich Räh
Industry Expert

ADVISORY BOARD

KEY FOCUS AREAS & PROJECT COMPANIES

 TECHNOLOGY PLATFORMS				
 BIOTECH & THERAPIES				
 MEDICAL TECHNOLOGY				
 ARTIFICIAL INTELLIGENCE				
				
				

ONCOLOGY	METABOLIC / INFLAMMATION	MEDICAL DEVICES	3D-PRINTING	DIAGNOSTICS	OBESITY
INVENTUMGENETICS iX Therapeutics QUADIRABIOSCIENCES VERAXA FUSE-AI XRNA BIOTECH	inflamed pharma Lysatpharma. NOVA XOMX BALIOPHARM FIRSTGENE xarma life sciences	Saniva vitruvia WE SUSTAIN ADDED VALUES	axenoll[®] 3D printing for life	Xkidney X nuclear	alytas therapeutics CRO Palleos

Our approach is to be in the driver seat. In over 50% of the new project companies, Xlife Sciences initiated the spin-off process directly from and with a university or research institution.



PROJECT STAGE

TECHNOLOGY PLATFORMS

	XLIFE	R&D	POC	EXIT
 INVENTUMGENETICS	2021	→		
 inflamed pharma	2019	→	→	
 Palleos	2019	→	→	
 VERAXA	2020	→	→	

BIOTECH & THERAPIES

	XLIFE	R&D	POC	EXIT
 alytas therapeutics	2019	→		
 BALIOPHARM	2021	→	→	
 Synimmune antibodies for life	2019	→	→	
 iX Therapeutics	2021	→	→	
 Lysatpharma.	2019	→	→	
 FIRSTGENE	2020	→		
 QUADIRABIOSCIENCES	2021	→	→	
 xarma life sciences	2020	→		
 XRNA BIOTECH	2023	→		


ARTIFICIAL INTELLIGENCE

	XLIFE	R&D	POC	EXIT
 FUSE-AI	2019	→	→	
 XDIAGNOSTICS	2021	→	→	

MEDTECH & DIAGNOSTIC

	XLIFE	R&D	POC	EXIT
 axenoll 3D printing for life	2019	→	→	
 LAXXON MEDICAL technology for your life	2019	→	→	
 Saniva	2019	→	→	
 vitruvia WE SUSTAIN ADDED VALUES	2019	→	→	
 nova xomx	2022	→		
 Xkidney	2019	→	→	
 X nuclear	2020	→	→	

Xlife Sciences has a recent focus on DACH. In the course of various business development activities, the network has expanded into EMEA, Asia and the US.




BUSINESS PARTNERS

Xlife Sciences is built on long-term relationships and a growing network with inventors, leading universities and scientific institutions.



Xlife Sciences synergies are a key driver of success. In the Xlife family, we live synergies. Many use cases and agreements have grown genuinely between our partners.



There is a high need for safer, more effective cancer drugs



40% of cancer patients do not survive.



Around **70%** of cancer therapies **fail** in phase 2.



Intolerable side effects and insufficient activity

Unique combination of technologies

Clinical stage asset

Broad IP portfolio



Attractive discovery pipeline:
Candidate outperforming a current blockbuster


Unique combination of technologies

Highly effective and cancer -specific therapies

Make untreatable cancers treatable by using a toolbox of technologies




Functional antibody screening



Site-specific antibody engineering tools



Advanced chemistry



Bi-targeted tumor associated cytotoxicity

The largest and fastest -growing therapeutic area



Bispecifics market: CAGR of **40%**, reaching 106bn in 2032

ADC market: CAGR of 10%, reaching USD 25 bn in 2032

PARTNER



INCORPORATION
2021

LOCATION
Zurich, Heidelberg

WEBSITE
www.veraxa.com

STAKE XLIFE
19%

Our motivations is to integrate ESG in the whole group, to incorporate personal values and to make a positive impact. Please find [here](#) our current ESG-Report and Code of Conduct.




NEXT STEPS & FOCUS


Having built up the portfolio over the last few years, the main task now is to achieve successful exits with project companies, strengthen liquidity and continue to grow.



**CASH
EVENTS**



**BRAND
AWARENES
S**



**ENHANCE
PIPELINE**



**INCREASE
LIQUIDITY**



**STRENGTHEN
TEAM**

We intend to carry out numerous projects as a license deal, trade sale or IPO. Below potential monetization events divided in two phases from near to mid-term future.




WHY XLIFE SCIENCES

With Xlife Sciences, we enable our shareholders to invest directly in a diversified early-stage life sciences portfolio in a liquid asset.




**LEAN AND COST-
EFFECTIVE
STRUCTURE**



**ACCESS TO A
DIVERSIFIED
PORTFOLIO**



**LIQUID
ASSET**



**DISCOUNTED
TRADE**

PLEASE GET IN TOUCH



> Oliver R. Baumann

Chief Executive Officer

oliver.baumann@xlifesciences.ch

+41 44 385 84 60



> Carl v. Halem

Chief Financial Officer

carl.halem@xlifesciences.ch

+41 44 385 84 58



> Dr. Alexander Zink

Chief Scientific Officer

alexander.zink@xlifesciences.ch

+41 44 385 84 60

where innovation leads to success

